Cargando…

A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients

Little is known about SARS-CoV-2 evolution under Molnupiravir and Paxlovid, the only antivirals approved for COVID-19 treatment. By investigating SARS-CoV-2 variability in 8 Molnupiravir-treated, 7 Paxlovid-treated and 5 drug-naïve individuals at 4 time-points (Days 0-2-5-7), a higher genetic distan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alteri, Claudia, Fox, Valeria, Scutari, Rossana, Burastero, Giulia Jole, Volpi, Sara, Faltoni, Matteo, Fini, Vanessa, Granaglia, Annarita, Esperti, Sara, Gallerani, Altea, Costabile, Valentino, Fontana, Beatrice, Franceschini, Erica, Meschiari, Marianna, Campana, Andrea, Bernardi, Stefania, Villani, Alberto, Bernaschi, Paola, Russo, Cristina, Guaraldi, Giovanni, Mussini, Cristina, Perno, Carlo Federico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753865/ https://www.ncbi.nlm.nih.gov/pubmed/36522489 http://dx.doi.org/10.1038/s42003-022-04322-8

Ejemplares similares

Is It Possible to Eradicate Carbapenem-Resistant Acinetobacter baumannii (CRAB) from Endemic Hospitals?
por: Medioli, Filippo, et al.
Publicado: (2022)

Epidemiology and Prevention of Early Infections by Multi-Drug-Resistant Organisms in Adults Undergoing Liver Transplant: A Narrative Review
por: Dolci, Giovanni, et al.
Publicado: (2023)

A case of SARS-CoV-2 Omicron reinfection resulting in a significant immunity boost in a paediatric patient affected by B-cell acute lymphoblastic leukemia
por: Scutari, Rossana, et al.
Publicado: (2023)

Ceftazidime/Avibactam in Ventilator-Associated Pneumonia Due to Difficult-to-Treat Non-Fermenter Gram-Negative Bacteria in COVID-19 Patients: A Case Series and Review of the Literature
por: Burastero, Giulia Jole, et al.
Publicado: (2022)

COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022
por: Wang, Lindsey, et al.
Publicado: (2022)

On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia
por: Boretti, Alberto
Publicado: (2023)

Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab
por: Franceschini, Erica, et al.
Publicado: (2023)

Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections
por: Gallerani, Altea, et al.
Publicado: (2023)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters
por: Bakos, Éva, et al.
Publicado: (2023)

Epidemiological characterization of SARS-CoV-2 variants in children over the four COVID-19 waves and correlation with clinical presentation
por: Alteri, Claudia, et al.
Publicado: (2022)

Publisher Correction: Epidemiological characterization of SARS-CoV-2 variants in children over the four COVID-19 waves and correlation with clinical presentation
por: Alteri, Claudia, et al.
Publicado: (2022)

Performance evaluation of a new on-demand molecular test for the rapid identification of severe acute respiratory syndrome coronavirus 2 in pediatric and adult patients
por: Colagrossi, Luna, et al.
Publicado: (2022)

Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections
por: Meschiari, Marianna, et al.
Publicado: (2021)

First Human Case of Tick-Borne Encephalitis in Non-Endemic Region in Italy: A Case Report
por: Barp, Nicole, et al.
Publicado: (2022)

Re: ‘Methodological evaluation of bias in observational COVID-19 studies on drug effectiveness’ by Wolkewitz et al.
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2021)

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
por: Wen, Wen, et al.
Publicado: (2022)

Identification of the bla(OXA-23) Gene in the First Mucoid XDR Acinetobacter baumannii Isolated from a Patient with Cystic Fibrosis
por: Rossitto, Martina, et al.
Publicado: (2023)

1979. Five-Year Impact of an Antimicrobial Stewardship Program on Nosocomial Candidemia: An Interrupted Time-Series Analysis Study
por: Bedini, Andrea, et al.
Publicado: (2019)

Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study
por: Mussini, Cristina, et al.
Publicado: (2023)

The Role of HIV Infection in Neurologic Injury
por: Scutari, Rossana, et al.
Publicado: (2017)

Evidence of pediatric sepsis caused by a drug resistant Lactococcus garvieae contaminated platelet concentrate
por: Colagrossi, Luna, et al.
Publicado: (2022)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

528. Matched Retrospective Study, Comparing Molnupiravir to Nirmatrelvir-Ritonavir (Paxlovid) in the Treatment of Mild-Moderate COVID-19 in Immunocompromised Cancer Patients
por: Haddad, Andrea, et al.
Publicado: (2023)

The Path to Paxlovid
por: Halford, Bethany
Publicado: (2022)

NZ's Pharmac negotiates deal for molnupiravir to treat COVID-19
Publicado: (2021)

Risks of paxlovid in a heart transplant recipient
por: Stawiarski, Kristin, et al.
Publicado: (2023)

Comorbidity Burden in Patients with Covid-19 Treated with Molnupiravir in the United States
por: Prajapati, Girish, et al.
Publicado: (2022)

Pneumocystosis as a Complication of H1N1 Influenza A Infection in an HIV-Positive Patient on Effective cART
por: Franconi, Iacopo, et al.
Publicado: (2019)

Disease Progression of Hospitalized Elderly Patients with Omicron BA.2 Treated with Molnupiravir
por: Liu, Yayun, et al.
Publicado: (2022)

The impact of tocilizumab on respiratory support states transition and clinical outcomes in COVID-19 patients. A Markov model multi-state study
por: Milic, Jovana, et al.
Publicado: (2021)

Epidemiology and Risk Factors Associated With Mortality in Consecutive Patients With Bacterial Bloodstream Infection: Impact of MDR and XDR Bacteria
por: Santoro, Antonella, et al.
Publicado: (2020)

The future of Paxlovid for COVID-19
por: Burki, Talha
Publicado: (2022)

Ranolazine Toxicity Secondary to Paxlovid
por: Casey, Bradley, et al.
Publicado: (2023)

28 Experiences of using Paxlovid to treat clinically extremely vulnerable non-hospitalised patients with COVID-19
por: Gahir, Joshua, et al.
Publicado: (2022)

Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature
por: Bacca, Erica, et al.
Publicado: (2021)

Quality of life and intrinsic capacity in patients with post-acute COVID-19 syndrome is in relation to frailty and resilience phenotypes
por: Guaraldi, Giovanni, et al.
Publicado: (2023)

Paxlovid with Caution: Novel Case of Paxlovid-Induced Tacrolimus Toxicity in a Cardiac Transplant Patient
por: Shah, Aaisha, et al.
Publicado: (2022)

Blackwater Fever Treated with Steroids in Nonimmune Patient, Italy
por: Di Biase, Anna Rita, et al.
Publicado: (2023)

Paxlovid™ jetzt direkt an Patienten abgeben
por: Zimmermann, Gerd W.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_emuoe4br41rms9adlbuq9uf8rq